Global Mild Cognitive Impairment Market Insights Forecasts to 2030
- The Global Mild Cognitive Impairment Market Size was valued at USD 2.1 Billion in 2022.
- The Market is growing at a CAGR of 5.24% from 2022 to 2032.
- The Worldwide Mild Cognitive Impairment Market size is expected to reach USD 3.5 Billion by 2032.
- Asia Pacific is expected to grow the fastest during the forecast period.
Get more details on this report -
The Global Mild Cognitive Impairment Market Size is expected to reach USD 3.5 Billion by 2032, at a CAGR of 5.24% during the forecast period 2022 to 2032. Some medical conditions, such as high blood pressure, diabetes, and heart disease, can increase the risk of mild cognitive impairment market. These conditions can affect blood flow to the brain and contribute to cognitive decline.
The mild cognitive impairment (MCI) refers to a stage of memory loss or other cognitive ability loss (such as language or visual/spatial perception) in people who can still carry out the majority of daily duties on their own. Several variables can lead to mild cognitive impairment, and individuals who already have it may develop dementia. For neurodegenerative diseases like Alzheimer's, MCI is a stage of the disease. Some patients with mild cognitive impairment may recover to stable cognitive abilities. The global mild cognitive impairment market includes products and services such as drugs, diagnostic tests, and therapies aimed at managing and treating the condition. The market is expected to grow significantly in the coming years, driven by an aging global population and increased awareness of cognitive impairment. Several pharmaceutical companies are actively engaged in the development of drugs for the treatment of mild cognitive impairment, with some of the leading players including Pfizer, Novartis, and Eli Lilly.
This research report categorizes the global mild cognitive impairment market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global mild cognitive impairment market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the global mild cognitive impairment market. Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market.
Global Mild Cognitive Impairment Market Report Coverage
|Market Size in 2022:||USD 2.1 Billion|
|Forecast Period 2022-2032 CAGR:||CAGR of 5.24%|
|2032 Value Projection:||USD 3.5 Billion|
|Historical Data for:||2020 to 2022|
|No. of Pages:||185|
|Tables, Charts & Figures:||97|
|Segments covered:||COVID-19 Impact Analysis, By Disease Type, By Age, By Indications, By Region, Growth Factors & Challenges.|
|Companies Covered:||Pfizer Inc., Hoffman La Roche Ltd., Novartis AG, Accord UK Ltd, Reddys Laboratories Ltd, Hikma Pharmaceuticals PLC, Sun Pharmaceuticals Ltd, Johnson & Johnson Services, Inc, Teva Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company Limited, Merck & Co Inc., SBI Pharmaceuticals Co Ltd and Among Others.|
Get more details on this report -
As people get older, they are more likely to experience cognitive decline and memory problems. The demand for products for moderate cognitive impairment is mostly driven by the growing elderly population around the world. For example, the National Institute on Aging reports that those with mild cognitive impairment are more likely than those without it to acquire hypertension or dementias of a similar nature. An estimated 10 to 20% of elders 65 and older with mild cognitive impairment develop dementia over a year. Also, some studies have suggested that certain genetic factors may contribute to the development of mild cognitive impairment. For example, the presence of the APOE ε4 allele has been associated with an increased risk of cognitive decline and Alzheimer's disease. Also, certain lifestyle factors, such as a lack of physical activity, poor diet, and smoking, have been associated with an increased risk of cognitive decline and mild cognitive impairment. A history of traumatic brain injury (TBI) has been associated with an increased risk of cognitive decline and mild cognitive impairment.
The several restraining factors that can impact the growth of the global mild cognitive impairment (MCI) market, such as developing new drugs and therapies for mild cognitive impairment can be a time-consuming and costly process. This can make it difficult for smaller companies to enter the market and for existing companies to invest in research and development. Also, there is often a stigma associated with cognitive decline and memory problems, which can make it difficult for people to seek help or for caregivers to provide support. In addition, many people are not aware of the signs and symptoms of mild cognitive impairment, which can delay diagnosis and treatment. The Economic downturns and changes in healthcare policy can impact the availability of funding for research and development, which can impact the growth of the mild cognitive impairment market. Moreover, despite ongoing research, there is still much that is not understood about mild cognitive impairment and its underlying causes. This can make it difficult to develop effective treatments and diagnostic tools.
In 2022, the amnestic segment is driving the market with the largest market share over the forecast period.
Based on the disease types, the global mild cognitive impairment market is classified into amnestic mild cognitive impairment, & non-amnestic mild cognitive impairment. Among these, the amnestic segment held the largest market share over the forecast period due to rising the older population across the globe. Amnestic mild cognitive impairment refers to a condition in which a person's memory deficits are worse than usual for their age and educational level but not severe enough to interfere with day-to-day activities. Amnestic mild cognitive impairment patients may start losing track of appointments, discussions, and recent occurrences that they would normally be able to recall easily.
In 2022, the geriatric segment held the largest market share during the forecast period
Based on age, the global mild cognitive impairment market is classsified into child, adult, and geriatric. Among these, the geriatric segment is dominating the market over the forecast period owing to an increase in the number of geriatric people who are at risk worldwide. It can be identified by a decline in memory, attention, and cognitive function that is more pronounced than would be expected given age and educational background.
In 2022, the alzheimer’s disease segment is dominating the largest market during the forecast period.
Based on the indication, the global mild cognitive impairment market is bifurcated into lewy body dementia, parkinson's disease dementia, alzheimer’s disease, vascular dementia, and other Indications. Among these, alzheimer’s disease is projected the largest market share over the forecast period, this is due to the high prevalence of Alzheimer's disease, which accounts for the majority of mild cognitive impairment cases worldwide.
Regional Segment Analysis of the mild cognitive impairment market
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Rest of APAC)
- South America (Brazil and the Rest of South America)
- The Middle East and Africa (UAE, South Africa, Rest of MEA)
North America is influencing the market with the largest market share over the forecast period
Get more details on this report -
North America dominated the global market in terms of revenue share for the mild cognitive impairment market owing to, what can be attributed to an increase in Alzheimer's disease and other types of dementia cases, and an increase in R&D efforts to create innovative therapies. Also, rise in public awareness of mental health issues. Moreover, several market participants are working to implement strategic developments that will aid in market expansion. As an example, in June 2021, the US Food and Drug Administration approved Aduhelm (aducanumab) to treat Alzheimer's disease. This is anticipated to have some impact on the mild cognitive impairment market.
The Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to factors such as improving healthcare infrastructure due to increased government spending on it and the rising prevalence of target diseases like Alzheimer's & Parkinson's disease which have an impact on the rise in growth of mild cognitive impairment market.
The report offers the appropriate analysis of the key organizations/companies involved within the global mild cognitive impairment market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Pfizer Inc., Hoffman La Roche Ltd., Novartis AG, Accord UK Ltd, Reddys Laboratories Ltd, Hikma Pharmaceuticals PLC, Sun Pharmaceuticals Ltd, Johnson & Johnson Services, Inc, Teva Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company Limited, Merck & Co Inc., SBI Pharmaceuticals Co Ltd and Among Others.
List of Key Companies
- Pfizer Inc.
- Hoffman La Roche Ltd.
- Novartis AG
- Accord UK Ltd.
- Reddy’s Laboratories Ltd.
- Hikma Pharmaceuticals PLC
- Sun Pharmaceuticals Ltd.
- Johnson & Johnson Services, Inc.
- Teva Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- Merck & Co Inc.
- SBI Pharmaceuticals Co Ltd.
Key Target Audience
- Market Players
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
- In July 2022, The FDA has designated Roche's Elecsys Amyloid Plasma Panel as a breakthrough product to help in Alzheimer's disease early detection.
- In March 2022, In the United States, Teva Pharmaceutical Industries Ltd. introduced generic Revlimid (capsules containing lenalidomide).
This study forecasts revenue at global, regional, and country levels from 2022 to 2032. Spherical Insights has segmented the global mild cognitive impairment market based on the below-mentioned segments:
Global Mild Cognitive Impairment (MCI) Market, By Disease Type
- Amnestic mild cognitive impairment
- Non-Amnestic mild cognitive impairment
Global Mild Cognitive Impairment Market, By Age
Global Mild Cognitive Impairment Market, By Indication
- Lewy Body Dementia
- Parkinson's Disease Dementia
- Alzheimer’s Disease
- Vascular Dementia
- Other Indications
Global Mild Cognitive Impairment Market, By Regional Analysis
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Need help to buy this report?